Home > Insider Trading > Filing (0000899243-18-031411)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	Pharmaceutical Preparations (2834)	274326290

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1643756	G. John Aunins	C/O Seres Therapeutics, Inc. 200 Sidney Street Cambridge MA 02139	Chief Technology Officer & Evp	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-12-17	14,282	$6.39	75,250	No	4	S	Direct
Common Stock	Acquisiton	2018-12-19	10,000	$0.00	85,250	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	RESTRICTED STOCK UNITS	Disposition	2018-12-19	10,000	$0.00	10,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.2100 to $6.5900. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each restricted stock unit represents right to receive one share of Issuer common stock.
These restricted stock units have vested and settled as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018.